AtaiBeckley Inc. - Common Stock (ATAI)

President Trump wants to fast-track psychedelic research.

AtaiBeckley (NASDAQ:ATAI) shares are surging Monday as psychedelic biotechs rally on President Trump's executive order to fast-track reviews.

Trump is easing approval for psychedelic treatments for mental disorders.

Today’s Date: March 26, 2026 Introduction As the global mental health crisis reaches unprecedented levels, the pharmaceutical industry has been forced to look beyond traditional SSRIs toward more radical, rapid-acting interventions. At the forefront of this neuro-psychiatric revolution stands GH Research PLC (Nasdaq: GHRS), a Dublin-based biopharmaceutical firm that has just crossed a critical threshold [...]

GH001 showed symptom improvement, high remission rates, and sustained benefits in a Phase 2b trial for treatment-resistant depression.

Jefferies sees restrictions around non-recreational psychedelics eventually loosen up.

The company, which focuses on psychedelic-based medicine, had a busy few days on both the regulatory and financing fronts.

As of mid-October 2025, a compelling and diverse group of companies, spanning utilities, biotechnology, advanced materials, and defense, have seen their stocks reach impressive 52-week highs. This significant market event underscores a nuanced financial landscape where both defensive stability and high-growth innovation are being richly rewarded. The surge in valuations

Atai Life Sciences' BPL-003 shows strong Phase 2b results for treatment-resistant depression, with potential $2.5 billion sales by 2035.

Investors cheered good news from the lab delivered by the company.

Atai Life Sciences and Beckley Psytech report strong BPL-003 study results in treatment-resistant depression, with Phase 3 trials expected in 2026.

On Thursday, Cathie Wood-led Ark Invest executed significant trades, notably selling shares of Tempus AI Inc (NASDAQ:TEM) and buying shares of Brera Holdings PLC (NASDAQ:BREA),